ARAVIVE (ARAV)
(Delayed Data from NSDQ)
$0.04 USD
0.00 (0.00%)
Updated Jan 26, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
ARAVIVE, INC [ARAV]
Reports for Purchase
Showing records 1 - 20 ( 104 total )
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Pivotal PROC Failure and Significant Financing Overhang Push Us to Sidelines; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Phase 1b/2a Results Underscore Batiraxcept''s Growing Potential in ccRCC at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Clinical Profile for Batiraxcept in ccRCC Builds With Updated Phase 1b/2a Data; Full Presentation at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
KOL Event Highlights Potentially Transformative Upcoming Data Updates Across Batiraxcept Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Ready, Set, Pivotal; Phase 3 Trial of Batiraxcept in ccRCC Cleared to Begin 2H23.
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
1Q23 Results; All Eyes On PROC Phase 3 Readout Mid-2023; Reiterate Top PIck
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
2022 Results; Push to Pivotal PROC Data in Mid-23; Target Upped to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Updated Phase 1b/2 Data in ccRCC Continue to Impress; Reiterate Top Pick
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Batiraxcept Achieves Full Enrollment in AXLerate-OC Phase 3 Trial in PROC; Top-Line Data in Mid-2023; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
3Q22 Results; Batiraxcept Advancing On All Fronts; Top- Line Phase 3 PROC Readout On Track for Mid-2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Financing Aids Phase III Readout. Dilution Reduces PT to $10
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Very Bitter Dilution Pill to Swallow Though Runway Very Comforting Now; Target Adjusted to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Expand a Study, Cash a Check; Phase 3 PROC Study Accelerates to Completion
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
2Q22 Results; Batiraxcept Stays the Course; Updated ccRCC Phase 1b/2 Data Expected in 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J